Applying stem cell technology to liver diseases

Great excitement greeted the discovery a few years ago that certain cells from mice and humans could be reprogrammed to become inducible pluripotent stem cells (iPS cells), as they hold promise for cell replacement therapy and modelling human disease. Two independent research groups - one led by Ludovic Vallier, at the University of Cambridge, United Kingdom, and the other led by Holger Willenbring, at the University of California San Francisco - have now shown that both possibilities are true for iPS cell - derived liver cells known as hepatocytes...

Read the whole article on

More from